Stockscreener 앱 받기
10.42
6.46%
-0.72
전일 마감가:
$11.14
열려 있는:
$11.11
하루 거래량:
1.47M
Relative Volume:
0.91
시가총액:
$1.03B
수익:
$14.79M
순이익/손실:
$-191.78M
주가수익비율:
-5.3532
EPS:
-1.9465
순현금흐름:
$-172.86M
1주 성능:
-3.87%
1개월 성능:
+57.64%
6개월 성능:
+96.98%
1년 성능:
+92.25%
1일 변동 폭
$9.91
$11.11
1주일 범위
$9.91
$11.45
52주 변동 폭
$3.79
$11.45
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
10.42 | 1.03B | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Guggenheim | Buy |
| 2025-12-04 | 개시 | Needham | Buy |
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices - simplywall.st
Solid Biosciences Inc (SLDB) Institutional Confidence - TradingKey
Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions? - simplywall.st
Form 4 Solid Biosciences LLC For: 7 July By Investing.com - Investing.com South Africa
Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares - Stock Titan
Solid Biosciences updates gene therapy pipeline as investors watch clinical strategy - ad-hoc-news.de
Solid Biosciences (SLDB) Gains 2.12% as Biotech Momentum BuildsBreakout Stock Alerts - dars.gov.et
Solid Biosciences (SLDB) Surges 6.27% as Biotech Sentiment ImprovesTrend Reversal Picks - dars.gov.et
Solid Biosciences stock hits 52-week high at $10.44 By Investing.com - Investing.com Canada
Solid Biosciences: The Bull Case Is No Longer Just Duchenne - Seeking Alpha
Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story? - simplywall.st
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base? - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Solid Biosciences Inc. - GuruFocus
Solid Biosciences Inc. connects with patients and stakeholders at 2026 annual Duchenne event - Traders Union
Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2500 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000E Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Enterprise value to EBITDA forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to book forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to earnings forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
SLDB Forecast — Price Target — Prediction for 2027 - TradingView
Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB) - TradingView
Solid Biosciences Inc. joins BAA 10K to fund cancer research advancement - Traders Union
Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com - Investing.com Australia
RA Capital discloses large SLDB stake with 8.18M pre-funded warrants - Stock Titan
RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership - Stock Titan
Solid Biosciences Inc. joins Parent Project Muscular Dystrophy event to connect Duchenne community - Traders Union
Solid Biosciences Inc.(NasdaqGS: SLDB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target - timothysykes.com
SLDB Jumps As Analyst Hikes Price Target To $25 - timothysykes.com
SLDB Jumps As H.C. Wainwright Hikes Price Target To $25 - timothysykes.com
Selling US$823k Of Solid Biosciences Stock Rewarded Insiders - Moomoo
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Sahm
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Solid Biosciences Inc (SLDB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Solid Biosciences Inc (SLDB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego - Traders Union
Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Solid Biosciences Inc (SLDB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Solid Biosciences Inc (SLDB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):